NCTN: A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone (CALGB-90202)
Getting access
No access information recorded yet.
About this database
| Last updated | 2026-08-25 |
|---|